Liberate Bio
Liberate Bio is focused on advancing non-viral delivery technologies for nucleic acid cargoes, including ASOs, siRNAs, mRNAs, and encoded gene editors. Utilizing automation, in vivo high-throughput screening, and machine learning, the company aims to enhance the delivery of genetic medicines to disease-relevant tissues. Founded by leaders in nucleic acid therapeutics, Liberate Bio operates a hybrid business model with both an internal pipeline and partnered programs, positioning itself as a key player in the genetic medicine market.
Liberate Bio
Liberate Bio is focused on advancing non-viral delivery technologies for nucleic acid cargoes, including ASOs, siRNAs, mRNAs, and encoded gene editors. Utilizing automation, in vivo high-throughput screening, and machine learning, the company aims to enhance the delivery of genetic medicines to disease-relevant tissues. Founded by leaders in nucleic acid therapeutics, Liberate Bio operates a hybrid business model with both an internal pipeline and partnered programs, positioning itself as a key player in the genetic medicine market.